- Home
- OPHC vs NRXP Comparison
OPHC vs NRXP Comparison
Compare OPHC & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPHC | NRXP |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.9M | 54.2M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | OPHC | NRXP |
|---|---|---|
| Price | $5.56 | $2.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.50 | ★ $38.25 |
| AVG Volume (30 Days) | 40.3K | ★ 1.0M |
| Earning Date | 04-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17,095.98 | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | $7.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.91 | $1.65 |
| 52 Week High | $5.59 | $3.84 |
Technical Indicators
Market Signals| Indicator | OPHC | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 61.89 | 65.74 |
| Support Level | $4.88 | $2.81 |
| Resistance Level | N/A | $3.28 |
| Average True Range (ATR) | 0.12 | 0.22 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 87.12 | 71.18 |
Price Performance
Historical ComparisonAbout OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.